Study on the Improvement of Metabolic Indicators in Type 1 Diabetes Patients

NCT07144696 · tracked via the Priya Life Science China tracker

Sponsor

Peking University First Hospital

Phase

Not applicable

Started

2025-08-05

Last updated

2025-09-04

Condition(s) studied

Type 1 Diabetes Mellitus

Investigational drug(s) / intervention(s)

structured education and regular follow-up

structured education and regular follow-up: Regularly carry out structured diabetes courses for patients with type 1 diabetes and offline teaching at Peking University First Hospital. On the basis of structured courses, regular outpatient follow-up visits will be conducted for patients, with on-site visits conducted at the Endocrinology Clinic of Peking University First Hospital. The usual visit period is once every 1-3 months, and the specific follow-up time nodes will be determined by medical staff based on the patient\&#39;s condition. Each visit will last 1-3 hours, and each subject is expected to be followed up for 1 year. During each visit, collect the medical history and some personal information of the subjects, complete the routine physical examination, draw blood to test diabetes related indicators (including the determination of fasting

Study summary

In this study, type 1 diabetes patients from the outpatient department of Peking University First Hospital were selected as the research objects. The investigators plan to recruit 150 participants. Using the course and teaching plan of \"Take Control of My Life - Structured Education for Type 1 diabetes\" issued by the China Type 1 diabetes Alliance, offline teaching is carried out regularly for type 1 diabetes patients, aiming to improve participants' knowledge and skills of disease self-management and improve participants' self-management behavior. The course content includes diabetes diet, exercise, blood glucose monitoring, insulin injection, complication prevention, psychological adjustment, etc. The training will take place at Peking University First Hospital. On the basis of structured courses, regular outpatient follow-up will be further carried out for patients to standardize their treatment behavior, improve their blood sugar compliance rate and delay the occurrence and development of diabetes complications. The subject visit is conducted on-site at the Endocrinology Clinic of Peking University First Hospital. The usual visit period is once every 1-3 months, and the specific follow-up time is determined by medical staff based on the subject\'s condition. Each visit lasts 1-3 hours, and each subject is expected to be followed up for 1 year. During each visit, collect the medical history and some personal information of the subjects, complete the routine physical examination, draw blood to test diabetes related indicators (including the determination of fasting and postprandial blood glucose, C-peptide, glycosylated hemoglobin, islet autoantibodies, blood lipids, liver and kidney functions), and screen diabetes complications. At the time of enrollment and after 1 year of follow-up, diabetes related questionnaires mainly related to diabetes self-management behavior and psychological emotions.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * ≥ 18 years old; * It meets the WHO diagnostic criteria for diabetes and is diagnosed as type 1 diabetes; * Capable and willing to participate in a 12 hour structured education course training; * Capable and willing to accept regular outpatient follow-up visits; * Voluntarily participate in this study and sign informed consent. Exclusion Criteria: * Non adult type 1 diabetes, type 2 diabetes and other special types of diabetes; * Severe microvascular complications: proliferative retinopathy; Urinary albumin/creatinine\>300mg/g, or 24-hour urinary protein quantification\>1g/d; Uncontrolled painful diabetes neuropathy and significant diabetes autonomic neuropathy; * Individuals who have undergone vascular intervention or amputation due to acute cerebrovascular accidents, acute coronary syndrome, or peripheral arterial disease requiring hospitalization within the first 3 months of selection; * Blood pressure remains above 180/110mmHg and cannot be controlled within 160/110mmHg within one week; * Blood creatinine clearance rate is less than 30ml/min/1.73m2 (calculated according to CKDEPI formula), alanine aminotransferase is ≥ 3 times the normal upper limit, total bilirubin is ≥ 2 times the normal upper limit and lasts for more than 1 week; * Have used drugs that may affect blood sugar for more than one week within the past 12 weeks, such as oral/intravenous glucocorticoids, growth hormone, estrogen/progesterone, high-dose diuretics, antipsychotic drugs, etc; However, low-dose diuretics for blood pressure lowering purposes (hydrochlorothiazide\<25mg/d, indapamide ≤ 1.5mg/d), as well as physiological doses of thyroid hormones used for replacement therapy, are not subject to this restriction; * Systemic infection or severe accompanying diseases; Patients with malignant tumors or chronic diarrhea; * Other situations that cause participants to be unable to cooperate in completing the study, such as severe cognitive impairment, mental illness, etc. * The subject is uncooperative, unable to follow up, or the researcher determines that they may have difficulty completing the study. * Other situations deemed unsuitable for inclusion by researchers. The research doctor will determine whether you are suitable to participate in this study based on your actual situation and the inclusion and exclusion criteria in the research plan.

Primary outcome measure(s)

Glycated hemoglobin — At baseline and 1-year follow-up
Glycated hemoglobin between 4%\~6% is normal

Trial sites (1)

Facility	City	Region	Status
Peking University First Hospital	Beijing	China	Recruiting

More Peking University First Hospital trials in China

TreAtments and outComes in paTients With prImary CutAneous Lymphoma Recruiting

Comparison of MRI Artificial Intelligence-guided cTB Versus Routine cTB in Prostate Cancer Diagnosis Recruiting

Clinically Actionable Tumor-Associated Antigens in Prostate Cancer Active, not recruiting

Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery Recruiting

BBM-L101 Gene Therapy in Participants With LGMD2D/R3 Starting soon

Other trials for the same condition

Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes Recruiting

Effects Of Berberine Plus Inulin On Diabetes Care in Patients With LADA Starting soon

Establishment of Screening Pathway for High-Risk Population of Type 1 Diabetes Recruiting

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes Recruiting

Immunotherapy with Autologous Tregs in T1DM Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07144696 on ClinicalTrials.gov ↗ ← All trials in China